Atlas Trials

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

Clinical trial NCT04523272 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04523272
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Advanced Renal Cancer
Start date
2020-08-25
Primary completion
2025-06-01
Enrollment
528

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.